INKLING-MS

Treatment tested

• Ketamine
• Midazolam

  GABA-A receptor; anion channel positive allosteric modulator

Other measures (3)

Inclusion Criteria: * Subject must be a man or woman, 18 to 65 years of age, inclusive. * Subject must be medically stable based on physical examination, medical history, and vital signs * Subject must meet McDonald 2017 diagnostic criteria for multiple sclerosis based on the PI review of the medical records * Subject must complain from fatigue as one of their main symptoms and have a screening MFIS score equal or higher than the cutoff based on gender, age, and education displayed in Table-226 * Subject must be ambulatory (able to walk at least 20 feet using bilateral assistance) * Subject must have internet and email access and ability to use a computer or tablet or smartphone * Subjects that are currently taking medication for alleviating fatigue (such as amantadine, modafinil and armodafinil, and amphetamine-like psychostimulants) at Screening are eligible to participate unless the medication is one of the disallowed therapies (Table 3). Subjects taking a fatigue medication at the Screening visit must have been receiving a stable dose for at least four weeks before the Screening visit and be willing to continue the medication at the same dose for the duration of the study. Exclusion Criteria: * BDI-II score of more than 29 (indicating severe depression) * Having a known clear cause for secondary fatigue, such as untreated sleep apnea, untreated hypothyroidism, chronic liver disease, history of moderate to severe anemia (hemoglobin concentration of less than 9 gr/dl in men or less than 8 gr/dl in women). * Neurodegenerative disorders other than relapsing or progressive MS * Breastfeeding or pregnant * History of coronary artery disease or congestive heart failure * Uncontrolled hypertension at Screening (history of high blood pressure and screening systolic blood pressure >160 or diastolic blood pressure>100) * History of severe liver disease, including cirrhosis * Terminal medical conditions * Currently treated for active malignancy * Alcohol or substance abuse in the past year (except marijuana or other cannabinoids) * A history of intolerance or allergic or anaphylactic reaction to ketamine or midazolam * Clinically unstable medical or psychiatric disorders that require acute treatment as determined by the PI * History of severe or untreated coronary artery disease or history of congestive heart failure * History of prior ischemic or hemorrhagic stroke and cerebral vascular aneurysms. * History of recurrent seizures or epilepsy * Taking any disallowed therapy(ies), as noted in the protocol.

The proposed study is a single-center, phase II, randomized, double-blind, parallel-group, active-placebo-controlled trial of intravenous low-dose ketamine in patients with MS fatigue.